GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
EMERYVILLE, Calif., May 02, 2018 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that company management is scheduled to present at two upcoming investor conferences:
- Gregory T. Went, Ph.D., the company’s Founder, Chairman and Chief Executive Officer, is scheduled to present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 2:50 p.m. EDT
- Richard A. King, the company’s Chief Operating Officer, is scheduled to present at the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018 at 1:40 p.m. PDT
The presentations will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. Archived versions of the webcasts will be available via replay for 30 days following the presentations.
About Adamas Pharmaceuticals, Inc.
Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. The company is focused on the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and delivering on its pipeline of differentiated investigational programs. Those programs include: ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.
Contact:
Investors:
Ashleigh Barreto
Director, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
510-450-3567
[email protected]
Media:
Terri Clevenger
Continuum Health Communications
203-227-0209
[email protected]
